Compare Stocks

Medifocus, Inc., a medical technology company, develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate in Canada and the United States. The company owns technology platforms, including Endo-thermotherapy platform, a catheter-based focused heat technology platform that utilizes natural body openings to deliver microwave thermotherapy to the diseased sites; and Adaptive Phased Array (APA) Microwave Focusing platform, which directs focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. It also offers Prolieve Thermodilatation system, a medical device based on endo-thermotherapy for the treatment of benign prostatic hyperplasia. In addition, the company is developing APA 1000, a minimally invasive breast cancer treatment system, which is in pivotal Phase-III clinical trials. The company has a license agreement with Duke University for the development of heat-activated and tumor-targeted immunotherapy and gene therapy technology for the treatment of cancers and other diseases. Medifocus, Inc. is based in Toronto, Canada.

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.